Skip to content

Krystal Biotech

Recent events

Recent events tied to this brand in public sources.

Back to profile1 entries

  1. 2023

    FDA approves Krystal Biotech's Vyjuvek gene therapy

    The US Food and Drug Administration approved Krystal Biotech's Vyjuvek, a topical gene therapy for dystrophic epidermolysis bullosa (DEB).